MATN
Mateon Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 14, 9:17 AM
    | Mon, Nov. 14, 9:17 AM
  • Wed, Aug. 3, 8:06 AM
    | Wed, Aug. 3, 8:06 AM
  • Fri, Jun. 10, 10:02 AM
    • OXiGENE (OXGN +13.3%) announces that FDA has granted Orphan Drug status to CA4P for the treatment of glioma, a broad category of brain tumors that grow from glial cells, that includes glioblastoma multiforme (GBM).
    • Seven years of marketing exclusivity is provided post product approval. Also, CA4P was previously declared an Orphan Drug for the treatment of ovarian cancer, neuroendocrine tumors and certain thyroid cancers.
    | Fri, Jun. 10, 10:02 AM | 1 Comment
  • Tue, May 24, 9:10 AM
    • Thinly traded nano cap OXiGENE (NASDAQ:OXGN) is up 65% premarket on a 9x surge in volume in response to its announcement of successful results in a Phase 2 clinical trial, called Study GOG-01861, assessing lead product candidate, Fast Track-tagged CA4P (fosbretabulin), in women with recurrent ovarian cancer. The results were just published online in the Journal of Clinical Oncology.
    • The open-label U.S.-based study randomized 107 patients across 67 sites to receive either CA4P with bevacizumab [Roche's (OTCQX:RHHBY) Avastin] or bevacizumab alone (control). It achieved its primary endpoint of showing a statistically valid improvement in progression-free survival (PFS) for the combination compared to Avastin alone (7.3 months versus 4.8 months; p=0.05).
    • Preliminary median overall survival also favored the CA4P combination (24.6 months vs. 22.0 months), with a 15% reduction in the risk of cancer progression or death (hazard ratio: 0.85).
    • No treatment-emergent serious adverse events were observed. The most common CA4P combination-related adverse events (grade 3 or higher) were hypertension (35%; n=18) versus 20% (n=10) for control.
    • CA4P is a vascular disrupting agent. It fights tumors by compromising the blood vessels that feed them, causing widespread ischemia (insufficient blood flow) and necrosis (tissue death) of the cancer cells within the core of the tumor.
    • A 436-subject Phase 2/3 study assessing CA4P + bevacizumab in platinum-resistant ovarian cancer is about to start. According to clinicaltrials.gov, the estimated study completion date is July 2018.
    | Tue, May 24, 9:10 AM | 4 Comments
  • Mon, May 9, 8:15 AM
    • OXiGENE (NASDAQ:OXGN): Q1 EPS of -$0.13 beats by $0.06.
    | Mon, May 9, 8:15 AM
  • Wed, Mar. 30, 10:48 AM
    • The FDA designates OXiGENE's (OXGN +12.1%) CA4P (combretastatin-A4 phosphate or fosbretabulin) for Fast Track review for the treatment of platinum-resistant ovarian cancer.
    • CA4P is a vascular disrupting agent. It fights tumors by compromising the blood vessels that feed them, causing widespread ischemia (insufficient blood flow) and necrosis (tissue death) of the cancer cells within the core of the tumor.
    • Fast Track status shortens the FDA's review clock to six months from the standard 10 months.
    • A 436-subject Phase 2/3 study will commence in April or May. According to clinicaltrials.gov, the primary endpoint is progression-free survival over at least 12 months. The estimated study completion date is July 2018.
    | Wed, Mar. 30, 10:48 AM | 3 Comments
  • Mon, Mar. 28, 8:43 AM
    • OXiGENE (OXGN) FY15 results: Revenues: $0; R&D Expense: $9.1M (+23.0%); SG&A: $4.6M (-11.5%); Net Loss: ($13.7M) (-8.7%); Loss Per Share: ($0.54) (+28.0%); Quick Assets: $27.3M (-9.0%).
    • No guidance given.
    | Mon, Mar. 28, 8:43 AM | 1 Comment
  • Mon, Mar. 28, 8:35 AM
    • OXiGENE (NASDAQ:OXGN): FY15 EPS of -$0.54
    | Mon, Mar. 28, 8:35 AM
  • Dec. 17, 2015, 3:25 PM
    • The European Commission designates OXiGENE's (OXGN +10.7%) investigational OXi4503 an Orphan Drug for the treatment of acute myeloid leukemia (AML). If approved, it will have a ten-year period of market exclusivity for the indication.
    • The FDA designated it an Orphan Drug for AML in November, 2012. If approved, it will have a seven-year of market exclusivity in the U.S.
    • OXi4503 (combretastatin A1 di-phosphate/CA1P) is a dual mechanism vascular disrupting agent. In cancer, it blocks and destroys tumor vasculature which leads to extensive tumor cell death and necrosis (tissue death).
    | Dec. 17, 2015, 3:25 PM
  • Nov. 11, 2015, 9:26 AM
    • OXiGENE (OXGN) Q3 results: Revenues: $0; R&D Expense: $2.5M (+13.6%); SG&A: $1.1M (-8.3%); Net Loss: ($3.6M) (-2.9%); Loss Per Share: ($0.14) (+17.6%); Quick Assets: $30.3M (+1.0%).
    • No guidance given.
    | Nov. 11, 2015, 9:26 AM
  • Nov. 10, 2015, 4:38 PM
    • OXiGENE (NASDAQ:OXGN): Q3 EPS of -$0.14 misses by $0.01.
    | Nov. 10, 2015, 4:38 PM
  • Sep. 30, 2015, 12:43 PM
    | Sep. 30, 2015, 12:43 PM | 10 Comments
  • Sep. 4, 2015, 12:45 PM
    | Sep. 4, 2015, 12:45 PM | 1 Comment
  • Aug. 4, 2015, 4:03 PM
    • OXiGENE (NASDAQ:OXGN): Q2 EPS of -$0.13 misses by $0.03.
    | Aug. 4, 2015, 4:03 PM
  • Jul. 20, 2015, 4:03 PM
    • OxiGENE (NASDAQ:OXGN) appoints Matthew Loar as Chief Financial Officer. Previously, he was CFO at privately held KineMed.
    | Jul. 20, 2015, 4:03 PM
  • Jun. 4, 2015, 6:54 AM
    • OxiGENE (NASDAQ:OXGN) Chief Financial Officer Barbara Riching resigned yesterday to pursue other interests. A successor has yet to be named.
    | Jun. 4, 2015, 6:54 AM | 4 Comments